Market Cap | 11.01M | P/E | - | EPS this Y | 75.30% | Ern Qtrly Grth | - |
Income | -27.02M | Forward P/E | -1.70 | EPS next Y | 35.00% | 50D Avg Chg | -4.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -58.00% |
Dividend | N/A | Price/Book | 3.23 | EPS next 5Y | - | 52W High Chg | -96.00% |
Recommedations | 3.00 | Quick Ratio | 0.61 | Shares Outstanding | 24.86M | 52W Low Chg | 34.00% |
Insider Own | 8.81% | ROA | -89.40% | Shares Float | 22.08M | Beta | 3.62 |
Inst Own | 13.54% | ROE | -1,598.05% | Shares Shorted/Prior | 64.46K/105.39K | Price | 0.44 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 271,340 | Target Price | 0.64 |
Oper. Margin | - | Earnings Date | - | Volume | 67,856 | Change | 12.41% |
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California. As of August 23, 2023, Apexigen, Inc. operates as a subsidiary of Pyxis Oncology, Inc..
EF Hutton | Hold | May 26, 23 |
EF Hutton | Hold | May 24, 23 |
EF Hutton | Buy | May 16, 23 |
EF Hutton | Buy | Jan 5, 23 |